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TECHNICAL NOTE
Capillary gas chromatography measurement of oxalate in
plasma and urine
MICHELLE LOPEZ, MENDEL TUCHMAN, and JON I. SCHEINMAN
Department of Pediatrics, University of Minnesota Hospital, Minneapolis, Minnesota, and Duke University Medical Center,
Durham, North Carolina, USA
Oxalic acid can be measured reliably in urine by colorimetric
methods [1] and is useful for the diagnosis of hyperoxaluric
states that result in nephrolithiasis. The measurement of plasma
oxalic acid has been far more difficult due to its very low
concentration in normal plasma and a variety of methodologic
problems. Normal plasma oxalic acid, measured by in vivo
isotopic dilution, has been reported in the range of —l
mo1es/liter (-9 g/dl) [2—4]. Far higher values, obtained by
most published methods [5, 6] suggest a lack of specificity that
would obscure variations in normal levels. The difficulty in
preserving specimens, the lack of a way of monitoring interfer-
ence, and the need for very large sample volumes makes
enzymatic methods [7] less than ideal.
Recently, Wolthers and Hayer [81 reported a capillary gas
chromatographic method for measuring plasma oxalic acid that
gave a normal range closer to that obtained by in vivo isotopic
dilution [41. We have adapted and verified this method for
measuring urinary and plasma oxalic acid and applied the
method to normal adults and patients with primary
hyperoxaluria. These patients have been studied during renal
insufficiency, during hemodialysis, and with various levels of
renal function after renal transplantation.
Methods. Urine specimens were collected for 24 hr on ice,
acidified to a pH of less than 2.0 with HCI (1:100 v/v), and
frozen at —20°C or —70°C until analysis. To triplicate 0.5 ml
samples we added malonic acid (15 pg), a further two drops of
6 N HCI, and 1 g NaC1. Heparinized blood was collected on ice,
the plasma separated (X2000 g, 20 mm) within 1 hr of collec-
tion, and 0.5-ml aliquots acidified with two drops of HC1 and
frozen (—70°C) in microfuge tubes (Sarsted). Samples were
partially thawed to transfer of the frozen/precipitated sample,
containing 2 g of malonic acid and 1 g NaC1, with one rinse of
0.5 ml of 0.1 N HCI. For either urine or plasma aliquots, a 4-mm
vigorous solvent extraction with 6 ml of ethyl acetate was
performed twice. Ethyl acetate was evaporated at 35°C under
anhydrous N2, placed under P205 in vacuo for 30 mm and
organic acids derivatized in the same tube with 50 to 150 (urine)
or 30 tl (plasma) of 30:1 (v/v) mixture of bis-trimethylsilyl-
trifluoroacetamide (BSTFA) (Regis Chemical Co., Morton
Received for publication July 24, 1984,
and in revised form December 11, 1984
© 1985 by the International Society of Nephrology
Grove, Illinois, USA) with bromotrimethylsilane (TMBS)
(Sigma Chemical Co., St. Louis, Missouri, USA) prepared
freshly each day. Tubes were tightly capped, heated at 80°C for
is mm, and 2 1d injected into the column within 6 hr.
Capillary gas chromatography (CGC) was performed on a gas
chromatograph (Model 5880-A, Hewlett-Packard, Elkhart, In-
diana, USA) equipped with an automatic sample injector, two
split-mode capillary injection ports, and two-flame ionization
detectors. Peak areas were integrated automatically from the
detector signals. The di-TMS derivatives of oxalic (mw 234) and
malonic (mw 248) acids from urine samples were separated on
a fused silica capillary column (25 m x 0.31 mm I.D.) with a film
0.52 pm thick and a stationary phase of 5% phenylmethyl
silicone, Ultra-2 (Hewlett-Packard). Because of an interfering
substance in plasma, these were analyzed on an Ultra-l column
(Hewlett-Packard) with a film thickness of 0.17 m, and a
stationary phase of 5% methyl silicone, Ultra-l (Hewlett-
Packard). The carrier helium flow rate (linear velocity) was 21
cm/see, the injection port temperature was 250°C, and the
detector temperature was 300°C. The split ratio was 1:50 for
urine and 1:10 for plasma. The oven temperature was raised
from 50°C to 140°C over 18 mm, then to 300°C and held for 10
mm.
Results. The standard curves used for urine oxalic acid
determination, for the ranges of 1.25 to 20 and 6 to 100 g of
oxalic acid were completely linear, with a regression equation
of: peak areal20 equals g oxalic acid per sample. For the
plasma standards, the completely linear relationship was: peak
areal8O equals ig oxalic acid, over the range of 0.125 to 5 g.
Extraction efficiency and recovery studies, Solutions of '4C
oxalic (0.25 .t CiIml) (New England Nuclear Corp., Boston,
Massachusetts, USA) and '4C malonic (0.125 Cilml) acids in
0.1 N HC1 were added to triplicate normal urine aliquots,
documenting a maximum extraction efficiency under the condi-
tions described, of 83 4.6% for oxalic and 88 4.6% for
malonic acids. For plasma, in the presence of added unlabelled
oxalic and malonic acids at levels of 0, 0.2, 0.5, 2.5 and 5 tg,
extraction efficiencies ranged from 70 to 85%. There was no
greater than a 6% difference between malonic and oxalic acids.
The overall recovery of unlabelled oxalic acid (at 6, 12.5, 25,
50, and 100 g) and malonic acid (100 tg) measured in normal
urine samples by CGC, for malonic acid was 93 6.3% and for
oxalic acid was 89 8%. A separate series of recovery studies
over the range of (added) oxalate of 25 to 200 g gave 93 11%,
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and for the range of 50 to 150 95 7%. The overall oxalic
acid recovery, over the range of 125 ng to 4 g, after the
correction of the peak area for the malonic acid internal
standard area, was 0.83 19% on nine samples for plasma.
There was complete stability of triplicate samples run four
times, from 6 hr to 6 months after acidification and freezing at
—70°C.
Urinary oxalic acid was measured on 24-hr urine samples
from a clinic population with recurrent nephroliathias. The
population mean for the CGC method was 36.1 19.7 (SD)
mg/24 hr excretion, N = 19. Duplicate samples (courtesy of Dr.
Charles Smith) analyzed by the method of Hodgkinson [1] gave
36.70 14.2 mg/24 hr; r = 0.636, P < 0.003. The coefficient of
variation for the CGC method was 12%, N = 12.
Normal plasma oxalate was determined on triplicate samples
from 16 healthy adult volunteers. The mean oxalate concentra-
tion (corrected for 83% recovery) without an internal standard
correction was 352 70 (SD)ng/mlin the range 246 to 540 ng/ml
with the median value of 341 ng/ml. Corrected for the malonic
acid internal standard, the normal plasma oxalate was 443 74
nglml, range 309 to 550 ng/ml, median 449 ng/ml (0.045 mgldl).
The coefficient of variation was 11.4% (N = 9), with or
without correction for the internal standard.
In patients with primary hyperoxaluria with stable renal
function [9], plasma oxalate was correlated with serum creati-
nine, corrected for 1.73 m2 body surface area: r = 0.818, P =
0.002, N 11. The most likely linear relationship is: oxalate
(mg/dl) = Con- Cr (mg/dl)/5.2.
Endogenous oxalate and creatinine clearances were mea-
sured seven times in five patients with primary hyperoxaluria.
The clearance ratios of oxalate to creatinine varied from 0.26 to
2.7. Elevated plasma oxalate (0.16 mg/dl) was found even in a
patient with good renal function (creatinine clearance 67
mllmin) 7 years after transplantation. A proportionately high
ratio of plasma oxalate to creatinine (in mg/dl) within I month of
transplantation (three measurements), (0.321.9, 0.42/1.0,
1.2/1.5) suggests the slower excretion of the pool of oxalate than
that of creatinine. This was also reflected in the high (> 500
mg/24 hr) urinary oxalate excretion in these patients. Continued
high plasma oxalate to creatinine ratios (0.95/2.8, 1.2/1.4)
months after transplant in two patients were accompanied by
recurrent deposition of oxalate in the transplanted kidney [9].
Dialysance of oxalate was determined for three adults and
one infant with hyperoxaluria from simultaneous arteri-
al/venous plasma determinations and calibrated hemodialysis
blood flow. For five clearances in adults using a cupraphane
hollow-fiber dialyzer, at flow rates from 150 to 350 mllmin, the
oxalate/creatinine clearance ratio was 0.88 0.09 (SD), the
oxalate/urea clearance ratio was 0.73 0.03. The
creatinine/urea clearance ratio was 0.83 0.09. For four
clearances in the infant, using the unipuncture technique and a
plate dialyzer at flows of 10 to 40 mI/mm, the oxalate/creatinine
clearance ratio was 0.95 0.03, the oxalate/urea clearance ratio
0.85 0.06 and creatinine/urea clearance ratio was 90 0.04.
Discussion. The present study documents a CGC assay for
plasma and urinary oxalic acid. Normal plasma oxalic acid
values (4.9 0.8 M, 0.044 0.007 mg/dl) are close to the range
of those obtained by isotopic dilution methods and far lower
than those by most previous methods [7, 10]. The method has
the sensitivity necessary to follow, in small sample sizes, the
changes in plasma oxalate in normal subjects, in hyperoxaluric
patients at different levels of renal function after transplanta-
tion, and in measuring renal and dialysis oxalate clearances.
The CGC method measures the di-TMS derivative of oxalic
acid. The variability of results (± 12%) derives from the use of
malonic acid di-TMS as an internal standard, which can break
down to the mono-TMS derivative, most notably beyond 6 hr
after derivatization. This variability is similar to those of most
other methods [11]. Samples can be preserved successfully,
without special preservatives [12], and interfering substances
can be identified on the chromatogram. CGC can also provide
data on the important precursors of oxalic acid (glycollic,
glyoxylic, and glyceric acids) that can assess the effects of
metabolic manipulations on the synthesis and excretion of
oxalic acid.
A practical application of dialysis clearances is the ability to
customize dialysis for oxalosis [9]. In an adult patient with a
plasma creatinine of 10 mg/dl, corresponding to an oxalate
value of 1.5 mg/dl, a urea clearance of 160 mI/mm, and an
oxalate clearance of 120 mi/mm, 540 mg of oxalic acid could be
removed in a 6-hr dialysis, which represents approximately
twice the daily production in hyperoxaluric patients. With a
plasma creatinine of 4 mg/dl and a plasma oxalate of 0.75 mg/dl,
half that amount would be removed. Thus, daily dialysis could
remove more than the daily production of oxalate, both in
infants and adults. Hemodialysis clearance can be optimized for
hyperoxaluric patients whose usual course during dialytic ther-
apy has been catastrophic. The degree to which intensive
hemodialysis can deplete exchangeable stores of oxalate may
be reflected by the decrease in plasma oxalate, which then may
predict the success of transplantation.
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